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Key messages
What is already known about this subject?
 ► Disease tissue heterogeneity is postulated to 
play a major role in incomplete drug  
response related to diverse target  
expression levels and drug pharmacology. 
In established/long-standing RA distinct 
histological and molecular subtypes have been 
described.
 ► However, their relationship with clinical 
phenotypes (e.g. disease activity/ 
progression) and treatment response remains 
controversial.
What does this study add?
 ► This study provides: first-time evidence in  
early, treatment-naive RA patients of the 
existence in the synovium of three specific 
pathology subgroups (Lympho-myeloid,  
Diffuse-myeloid and Pauci-immune-fibroid), 
prior to the potential modification of  
disease pathology by immune-modulatory 
therapies.
 ► In addition, it demonstrates that specific 
histopathotypes and associated transcriptional 
endotypes define distinct RA subtypes that are 
linked to diverse clinical phenotypes, disease 
activity/severity and treatment response and 
that gene expression signatures associated 
with cellular infiltration in synovium strongly 
correlate with imaging modalities including 
ultrasonographic measures of synovial  
thickness and power Doppler and erosive load 
on x-ray.
 ► Moreover, longitudinal analysis demonstrated 
that specific synovial signatures are associated 
with response to DMARD therapy, clinical 
outcome at 6 months and radiographic joint 
damage at 12 months.
AbsTRACT
Objectives To unravel the hierarchy of cellular/molecular 
pathways in the disease tissue of early, treatment-naïve 
rheumatoid arthritis (ra) patients and determine their 
relationship with clinical phenotypes and treatment 
response/outcomes longitudinally.
Methods 144 consecutive treatment-naïve early ra 
patients (<12 months symptoms duration) underwent 
ultrasound-guided synovial biopsy before and 6 months 
after disease-modifying antirheumatic drug (DMarD) 
initiation. synovial biopsies were analysed for cellular 
(immunohistology) and molecular (nanostring) 
characteristics and results compared with clinical and 
imaging outcomes. Differential gene expression analysis 
and logistic regression were applied to define variables 
correlating with treatment response and predicting 
radiographic progression.
Results cellular and molecular analyses of synovial tissue 
demonstrated for the first time in early ra the presence 
of three pathology groups: (1) lympho-myeloid dominated 
by the presence of B cells in addition to myeloid cells; (2) 
diffuse-myeloid with myeloid lineage predominance but 
poor in B cells nd (3) pauci-immune characterised by scanty 
immune cells and prevalent stromal cells. longitudinal 
correlation of molecular signatures demonstrated that 
elevation of myeloid- and lymphoid-associated gene 
expression strongly correlated with disease activity, acute 
phase reactants and DMarD response at 6 months. 
Furthermore, elevation of synovial lymphoid-associated 
genes correlated with autoantibody positivity and elevation 
of osteoclast-targeting genes predicting radiographic 
joint damage progression at 12 months. Patients with 
predominant pauci-immune pathology showed less severe 
disease activity and radiographic progression.
Conclusions We demonstrate at disease presentation, 
prior to pathology modulation by therapy, the presence 
of specific cellular/molecular synovial signatures that 
delineate disease severity/progression and therapeutic 
response and may pave the way to more precise definition 
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Key messages
How might this impact on clinical practice?
 ► This study demonstrates that the cellular and molecular 
signatures define pathobiological endotypes early in the 
disease process, prior to treatment modification, that have 
a significant impact on disease prognosis and treatment 
outcome.
 ► This offers the potential for a more accurate patient 
stratification of this severe disabling disease where early 
disease modification is crucial to life course outcome and 
quality of life.
InTROduCTIOn
Better understanding of rheumatoid arthritis (RA) disease 
pathogenesis has led to the development of highly effective 
therapeutics inhibiting structural damage and improving prog-
nosis1; however, a sizeable proportion of patients (~40%) do 
not respond to these therapies and the mechanisms for response/
nonresponse remain unknown. Additionally, as currently it is not 
possible to predict which patients would benefit from individual 
therapeutic modalities, this leaves a huge unmet clinical need.
Disease tissue heterogeneity is postulated to play a major 
role in incomplete drug response related to diverse target 
expression levels and drug pharmacology. In established/long-
standing RA, distinct histological and molecular subtypes have 
been described.2 3 However, their relationship with clinical 
phenotypes (eg, disease activity/progression) and treatment 
response remains controversial. The reasons for such discrep-
ancies (reviewed3) include multiple confounding factors 
ranging from (i) small sample size (mostly 20–40 patient 
cohorts), (ii) reliance on cross-sectional rather than prospec-
tive data and (iii) inclusion of patients at different disease 
stages/severity and treated with multiple therapies potentially 
influencing synovial pathobiology.3
In addition, many studies have been performed in established/
late-stage disease and with a sampling bias due to prevalent repre-
sentation of large joints (arthroscopy/joint replacement) while 
only a handful of studies have included small joints.3 Further-
more, though molecular characterisation of synovial tissue has 
been recently published in established/long-standing RA,4 5 here 
we report the first systematic cellular (immunohistology) and 
molecular (NanoString) characterisation in early disease, treat-
ment-naïve patients.
We demonstrate at disease presentation, prior to potential 
modification by therapy, the presence of three distinct pathology 
groups: (1) lympho-myeloid dominated by lymphoid lineage 
infiltration (T cells, B cells, plasma cells) in addition to myeloid 
cells; (2) diffuse-myeloid with myeloid lineage predominance 
but poor in B cells/plasma cells and (3) Pauci-immune character-
ised by scanty immune cells and prevalent stromal cells. Longi-
tudinal correlation of molecular signatures demonstrated that 
elevation of myeloid and lymphoid-associated gene expression 
strongly correlated with disease activity, acute phase reactants 
and conventional synthetics disease-modifying antirheumatic 
drugs (DMARDs) response at 6 months. Furthermore, elevation 
of synovial lymphoid-associated genes correlated with autoan-
tibody positivity and the elevation of osteoclast-targeting genes 
and predicted radiographic joint damage progression at 12 
months. Patients with predominant pauci-immune pathology 
showed less severe disease activity and radiographic progression 
but, importantly, lower therapeutic response.
MeTHOds
Pathobiology of early Arthritis Cohort
In all, 144 RA patients fulfilling 2010 American College of Rheu-
matology/European League Against Rheumatism (EULAR) Clas-
sification Criteria, with clinically defined synovitis and symptom 
duration less than 12 months, were enrolled as part of the ‘Patho-
biology of Early Arthritis Cohort’ (PEAC, http://www. peac- mrc. 
mds. qmul. ac. uk) at three UK Academic Centres: Queen Mary 
University of London/Barts Health NHS trust, University of 
Glasgow and University of Birmingham. All patients were naïve 
to steroid and DMARD therapy.
Patients underwent a ultrasound (US)-guided synovial biopsy 
(figure 1A) procedure we pioneered6 of a clinically active joint 
selected according to a previously defined algorithm to ensure 
maximal synovial tissue retrieval6; a minimum of 12 synovial 
biopsies were stored for subsequent analysis at the William 
Harvey research Institute (six for histological analysis and six 
for RNA extraction), and patients then commenced on stan-
dard DMARD therapy and/or low-dose corticosteroid. A treat-
to-target approach to therapy escalation was followed aiming 
for low disease activity score-28 (DAS28) <3.2. Patients failing 
DMARD therapy were commenced on biological therapy 
according to the UK National Institute for Clinical Excellence 
prescribing algorithm for RA patients if they continued to have a 
DAS28 >5.1 at 6 months.
Ultrasonographic images were collected at the time of biopsy 
for both the individual biopsied joint and the global joint score: 
first to fifth metacarpophalangeal (MCP) joints and midline, 
radial and ulnar views of both wrist joints. Images subsequently 
underwent semiquantitative assessment by a single blinded (to 
clinical/histological data) assessor for both synovial thickening 
(ST) and power Doppler (PD) activity according to standard 
EULAR-OMERACT (Outcome Measures in Rheumatology) 
US synovitis scores (grade 0–3).7 The mean global ST and PD 
scores including the maximal score for the wrist joint were then 
determined.
Plain radiographs of the hands and feet performed at baseline 
and 12-month follow-up were scored in time sequential order 
according to the van der Heijde modified Sharp score (SHSS) 
by a single reader blinded to all clinical/histological data. The 
study received local ethical approval (REC-05/Q0703/198) and 
all participants gave written informed consent.
Histology
Paraffin-embedded H&E stained sections were graded as suit-
able for further histopathological assessment if intact lining layer 
was identified. Following immunohistochemical staining for B 
cells (CD20), T cells (CD3), macrophages (CD68) and plasma 
cells (CD138) as previously reported,8 the degree of immune 
cell infiltration was determined semiquantitatively (0–4). Biop-
sies were then stratified into one of the three synovial groups 
according to the following criteria: (i) lympho-myeloid presence 
of grades 2–3—CD20+ aggregates, (CD20 ≥2) and/or CD138 
≥2; (ii) diffuse-myeloid—CD68 SL ≥2, CD20 ≤1 and/or CD3 
≥1, CD138 ≤2 and (iii) pauci-immune-fibroid—CD68 SL <2 
and CD3, CD20, CD138 <1.
nanostring gene expression analysis
NanoString Panels Construction. Pathotype-specific NanoString 
panels were developed based on a previous microarray study2 
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Figure 1 (A) Representative image of an US-guided wrist biopsy. Inset: greyscale transverse US image of wrist joint demonstrating biopsy needle 
entering joint space under extensor tendon complex. Synovial tissue fragment (encircled) in biopsy needle. (B) Patient characteristics of cohort. (C) 
Number and type of joints biopsied. (D) Synovial pathotype according to joint biopsied. (E) H&E staining and immunohistochemistry of synovial 
biopsies for CD20+ B cells, CD3+ T cells, CD68+ macrophages in synovial lining/sublining layers and CD138+ plasma cells from treatment-naïve 
individuals with early rheumatoid arthritis. Synovial biopsies were categorised as lympho-myeloid, diffuse myeloid or pauci-immune fibroid. CCP, cyclic 
citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score-28; ESR, erythrocyte sedimentation rate; MTP, metatarsophalangeal; MCP, 
metacarpophalangeal; PIP, proximal interphalangeal; RF, rheumatoid factor; SHSS, van der Heijde modified Sharp score; SJ, swollen joints; TJ, tender 
joints; US, ultrasound; VAS, visual analogue scale.
(GEO accession number GSE48780). Differential expression 
analysis was performed using the limma package.9 We performed 
all pairwise comparisons between samples in the pauci-immune, 
diffuse-myeloid and lympho-myeloid groups. Genes were 
selected for a pathotype if they showed differential expression 
with each of the other two pathotypes at a Benjamini-Hochberg 
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adjusted p value <0.01 (online supplementary figure 1A–C and 
online supplementary tables 1–3). These genes were validated 
in the baseline RNA-seq data (deposited in ArrayExpress acces-
sion code E-MTAB-6141) from the PEAC cohort. For each set 
of pathotype-specific genes, we identified the 50 genes that best 
correlated with the first principal component of the z-score 
transformed expression data for that gene set and included 
an additional set of 87 genes implicated in RA pathobiology 
(online supplementary table 3). We confirmed that expression 
levels determined by NanoString were concordant with those 
measured by RNA sequencing, in samples where both measure-
ments were available (online supplementary figure 2).
NanoString Analysis. Total RNA was extracted from synovial 
tissue using TRIzol Reagent (ThermoFisher Scientific, Life Tech-
nologies, Invitrogen Division, UK) as previously described.6 A 
custom CodeSet of capture and reporter probes was designed 
to target regions of 100 nucleotides of 242 genes. Hybridisa-
tion of 50–100 ng of synovial RNA was carried out according 
to the manufacturer’s instructions. Raw expression data were 
obtained using the NanoString nCounter MAX analysis system 
(NanoString Technologies, Seattle, WA, USA) according to the 
manufacturer’s instructions. Analyses of NanoString expression 
data were performed using R (V.3.3.2). For differential expres-
sion analyses, we used the limma Bioconductor package9 using 
default settings. We used the Benjamini-Hochberg method10 to 
adjust for multiple testing, and considered genes to be differen-
tially expressed if they had an adjusted p value <0.01. Eigengene 
scores were calculated as previously described,11 with statistical 
adjustment for biopsy joint position. The osteoclast gene set 
utilised was described in the Harmonizome database (http:// 
amp. pharm. mssm. edu/ Harmonizome/).
serum biomarker assessments
Serum samples from 111 patients at baseline were assessed for 
levels of soluble intercellular adhesion molecule 1 (sICAM1), 
C-X-C motif-chemokine-13 (CXCL13), interleukin-8 (IL-8) and 
matrix metalloproteinase-3 (MMP-3) using customised electro-
chemiluminescence assays incorporating sample diluent blocking 
reagents to minimise interference from heterophilic antibodies.
statistical methods
Statistical analyses of histological and clinical parameters and 
predictive modelling of progression were run using R.3.0.2. P 
values relating discrete variables to each other were calculated 
with the use of Fisher’s exact test. P values for correlation were 
derived using Spearman’s correlation. To account for multiple 
testing, we used the method of Benjamini and Hochberg to adjust 
p values. For correlations between clinical characteristics and 
eigengene values with adjustment for biopsy joint position, all 
p values from all comparisons were adjusted together. Likewise, 
for correlations between serum biomarkers and clinical charac-
teristics and histological parameters, p values were adjusted alto-
gether. P values for comparison of means between three groups 
were calculated using one-way analysis of variance with Bonfer-
roni post hoc test. All p values reported are two sided.
Selection of gene predictors: Backward stepwise selection 
method using logistic regression was performed using glm func-
tion in R, with 16 baseline clinical covariates considered as 
candidates in the regression model. A subset of predictors was 
selected by imposing a L1 (least absolute shrinkage and selec-
tion operator, LASSO) penalty on the regression parameters (46 
genes and 8 clinical covariates) of a sparse logistic regression 
using R package glmnet. The penalty parameter (lambda) was 
optimised by 10-fold cross-validation. Lambda tuned to the 
smallest mean cross-validated error was retained as final penalty 
parameter in the model.
Predictive performance evaluation: The predictive perfor-
mance of the models with and without the genes (respec-
tively, LASSO and backward stepwise models) was assessed by 
computing the area under the receiver operating character-
istic curve (AUC). Both apparent and internally validated AUC 
were assessed. To compensate for overfitting inherent to the 
apparent AUC, internal validation was performed to correct the 
measure of predictive performance for optimism using bootstrap 
(repeated 500 times) with the R-package boot V.1.3–18, as a 
valid method to generate unbiased optimism-adjusted estimates 
of the C statistic (AUC) with small absolute errors.
ResulTs
Patient cohort
Patient characteristics are summarised in figure 1B. Briefly, most 
patients had high disease activity (mean DAS28 5.6±SD 1.5), 
mean disease duration 5.6 months (SD 3.2), approximately 65% 
were positive for rheumatoid factor (RF) and/or anti-citrullinated 
peptide antibodies (ACPA), and 20% had at least one radiographic 
erosion. The joint biopsied most frequently was the wrist (~65%), 
with good additional representation from MCP/proximal inter-
phalangeal/metatarsophalangeal joints (~15%) and knee, elbow 
together ~20% (figure 1C).
Identification of synovial pathotypes by histopathology
In total, 129 of the 144 recruited patients (89.6%) had synovial 
tissue suitable for subsequent histological analysis (failure rate 
10.4%). Using the algorithm described in the Methods, we clas-
sified patients into three distinct synovial pathological groups 
(figure 1D): (1) lympho-myeloid (n=51, 39%) dominated by 
lymphoid lineage infiltration (T cells, B cells, plasma cells) in 
addition to myeloid cells; (2) diffuse-myeloid (n=44, 34%) with 
myeloid lineage predominance but poor in B cells/plasma-cells 
and (3) pauci-immune (n=34, 27%) characterised by fibroblasts 
expansion but scanty immune cells. When evaluating prevalence of 
pathotype according to joint biopsied, we noted a higher propor-
tion of pauci-immune pathotype in small- and medium-sized joints 
(figure 1D).
Identification of pathotype-specific gene expression markers
To determine the relationship of clinical characteristics with 
molecular profiling in pretreatment and post-treatment biopsies, 
we profiled gene expression of the 111 baseline and 68 post-treat-
ment samples using a custom NanoString panel. Unsupervised 
clustering of NanoString expression data showed strong grouping 
of pathotype-defined genes in concordance with their initial patho-
type assigned by histology (figure 2A). Samples classified as either 
lympho-myeloid or pauci-immune showed highest expression 
of the lymphoid or fibroid eigengene score, respectively, while 
samples classified as diffuse-myeloid had myeloid eigengene scores 
similar to the lympho-myeloid samples (figure 2B,C: Radar Plot). 
Furthermore, most genes measured significantly differed across the 
three groups; all but 1 of 212 genes had an adjusted p value <0.01 
(figure 2D). Eigengene scores were then examined against synovial 
aggregational scores demonstrating strong correlations with the 
level of inflammatory infiltrate organisation (online supplemen-
tary figure 3A,B). Comparing each pathotype to the others, we 
found that pauci-immune-fibroid eigengene scores were negatively 
correlated with lymphoid and myeloid eigengene scores, whereas 
lymphoid and myeloid scores were positively correlated (online 
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Figure 2 (A) Heatmap of NanoString gene expression data. Raw log2 NanoString counts for 212 genes and 111 patient samples were normalised 
per probe to give a mean of 0 and SD of 1. Normalised data were clustered by row and column using Euclidean distance and Ward’s linkage. Samples 
are coloured according to IHC-determined pathotype, with ungraded samples coloured grey. Rows are coloured according to the pathotype with 
which the gene was originally associated, with RA biology-associated genes coloured black. (B) Eigengene scores versus IHC-determined pathotypes. 
Individual eigengene scores are plotted for each sample, grouped and coloured by the pathotype as determined by IHC. Stars represent statistical 
significance as determined by linear regression across groups: *p<0.05, **p<0.01, ***p<0.001. (C) Radar plot of standardised eigengene scores. 
Eigengene values were normalised to give a mean 0 and SD of 1. Samples were grouped by pathotype, and the mean (solid lines) and SE of the mean 
(shaded region) were calculated for the normalised eigengenes. Spokes of the radar plot represent the distance along each normalised eigengene for 
each sample group. (D) Volcano plot of gene expression differences across pathotypes. For each gene, one-way ANOVA was performed comparing 
expression across the three pathotypes. The –log10 p value from the one-way ANOVA is plotted against the root mean square of the log2 fold changes 
between each pair of eigengenes. Genes are coloured according to the pathotype in which it was initially identified, with RA biology-associated genes 
coloured black. ANOVA, analysis of variance; IHC, immunohistochemistry; RA, rheumatoid arthritis.
supplementary figure 4A). Comparing myeloid pathotype samples 
with the other two yielded fewer differentially expressed genes, 
with lower expression of lymphoid-specific genes in these samples 
relative to the combined lympho-myeloid/pauci-immune-fibroid 
group (online supplementary figure 4B). This is consistent with the 
scoring algorithm used to determine the pathotypes: diffuse-my-
eloid samples mainly differ from lympho-myeloid samples by a 
relative lack of B- and T-cell infiltrate. Thus, the eigengene-specific 
gene sets show strong association with the expected pathotypes.
synovial pathotypes and clinical phenotypes
To establish the relationship between synovial pathotypes and 
clinical phenotypes, we compared a number of disease charac-
teristics with the three synovial pathotypes defined by immuno-
histochemistry (IHC), with statistical adjustment for biopsy joint 
position. The lympho-myeloid pathotype had the highest levels of 
erythrocyte sedimentation rate (ESR), C-reactive protein, ACPA 
titre, swollen-joint-counts and DAS28-ESR scores (figure 3A). 
Assessment of joint damage by SHSS indicated an association of 
the lympho-myeloid group with worse erosive load and joint space 
narrowing (figure 3A). Furthermore, ultrasonographic assessment 
indicated that the lympho-myeloid group had significantly higher 
levels of ST and PD scores both within the biopsied joint and overall 
scores. The pauci-immune group had the lowest levels of acute 
phase reactants, RF and ACPA positivity, and US scores despite 
the presence of active disease, documented by high DAS28-ESR 
(mean 4.9), swollen joint counts, Health Assessment Questionnaire 
(HAQ) and patient global health visual analogue scale (VAS) scores 
as well as synovitis determined by ultrasonography (figure 3A). 
The diffuse-myeloid group showed intermediate metrics.
lymphoid/myeloid gene expression signatures correlate with 
RA disease activity
Comparison of eigengene scores to features of disease activity 
(figure 3B) showed that the myeloid eigengene was highly asso-
ciated with disease activity, including acute phase reactant, 
DAS28-ESR, HAQ-Disability Index (DI) and overall PD ultraso-
nography score. The lymphoid eigengene was also correlated with 
disease activity, but at a lower level, and was more associated with 
ultrasonographic scores. In keeping with the histopathological 
correlations, the fibroid eigengene was negatively associated with 
many aspects of disease activity (figure 3B).
serum biomarkers reflect synovial pathophysiology
We next assessed if reported circulating serum biomarkers could 
function as surrogates of synovial tissue pathology2 and reliable 
measures of disease activity. We selected CXCL13, sICAM-1, 
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Figure 3 (A) Baseline clinical and histological parameters stratified according to three pathological subtypes, adjusted for joint type (n=129), 
*significant differences. (B) Correlation analysis of each Eigengene score with metrics of clinical disease activity, autoantibodies, acute phase 
reactants and ultrasonography. Values represent Spearman correlation coefficients between the clinical variables and the individual eigengene 
scores adjusted for joint type. Stars represent the significance of the correlation coefficient: *p<0.05, **p<0.01, ***p<0.001. ACPA, anti-citrullinated 
peptide antibodies; BJ, biopsied joint; CRP, C-reactive protein; DAS28, disease activity score-28; DI, Disability Index; ESR, erythrocyte sedimentation 
rate; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SHSS, van der Heijde modified Sharp score; SJ, swollen joints; ST, synovial 
thickening; TJ, tender joints; US, ultrasound, VAS, visual analogue scale.
MMP3 and IL-8 due to their important inflammatory roles in 
RA pathophysiology. CXCL13 and sICAM1 have been previously 
shown to be elevated in different synovial phenotypes,2 whereas 
MMP3 is also elevated in synovitis and associated with radio-
graphic progression.12 IL-8 drives tissue recruitment of neutrophils 
(polymorphonuclear neutrophils), which could play a role in syno-
vial autoimmunity through the exposure of citrullinated proteins 
by neutrophil extracellular traps.13 Consistent with previous 
reports,14 15 we found that serum CXCL13 correlated with global 
disease metrics, including DAS28, serological and ultrasonographic 
measures of disease activity and synovial histology (figure 4A,B). 
Serum MMP-3 also showed modest yet significant correlation 
with acute phase reactants, DAS28 score and synovial histology 
(figure 4A,B). Intriguingly, CXCL13 and MMP3 were both 
elevated in patients with a lymphoid–myeloid pathotype, compared 
with the other two pathotypes (figure 4C,D). In contrast, despite 
previous reports of elevated levels in RA patients,2 16 ICAM-1 
and IL-8 exhibited modest and variable correlations with clinical 
indices such as tender joint scores, acute phase reactants and auto-
antibody titres (figure 4A,B). Therefore, elevation of some but not 
all inflammatory proteins in the serum of RA patients tracks with 
synovitis and clinical disease activity.
Pretreatment synovial pathotypes gene expression signatures 
associate with response to dMARd treatment
Histologically defined pathotypes and gene expression signa-
tures were examined for their response to DMARD therapy as 
determined by change in DAS28-ESR at 6 months and EULAR 
response criteria (figure 5). Overall, 90% of patients were treated 
with methotrexate either alone or in combination (figure 5A).
Though histologically defined pathotypes did not associated 
with therapeutic outcome (figure 5A), differential gene expres-
sion analysis in EULAR good-responder patients showed that 
multiple inflammatory pathways were statistically significantly 
reduced including genes associated with lymphoid aggregates 
(CCL19, BTLA, IL21R, CXCL13, LTA, LTB) and inflammatory 
cytokines (IL6) (figure 5B). In contrast, nonresponder patients 
showed decrease in nonsignificant inflammatory gene expres-
sion (figure 5C).
We next assessed whether eigengene scores at baseline 
correlated with therapeutic response. Higher myeloid and 
lymphoid eigengene expression (but not fibroid) was associ-
ated with larger decreases in DAS28-ESR scores post-treatment 
(myeloid, p=0.003; lymphoid, p=0.044; figure 5D). Specific 
eigengene scores were then compared separately in good and 
nonresponders (figure 5E–G) determining that good DMARD 
response showed more dynamic gene expression, with signifi-
cant decreases in both lymphoid and myeloid eigengenes, but 
a concomitant increase in fibroid eigengene expression. Nonre-
sponders exhibited a more muted change in gene expression, with 
significant decrease in lymphoid eigengenes, but highly variable 
changes in myeloid and fibroid eigengene expression indicating 
ongoing presence of myeloid gene expression in patients with 
continuing disease activity despite DMARD therapy, but strong 
downregulation in responder patients.
synovial pathotypes and gene expression signatures predict 
radiographic progression
Next, we assessed whether baseline pathotypes or gene expres-
sion were associated with ongoing radiographic damage at 12 
months. Lympho-myeloid pathotype patients had a greater 
change in SHSS compared with diffuse-myeloid and pauci-im-
mune-fibroid patients (figure 6A). Importantly, of the 14 
patients subsequently commenced on biological therapy between 
6 and 12 months of follow-up, a higher proportion with radio-
graphic progression at 12 months fell within the lympho-my-
eloid pathotype (26.5%, 9 progressors vs 25 nonprogressors), 
as compared with the diffuse-myeloid/pauci-immune-fibroid 
pathotypes (9.1%, 5 progressors vs 50 nonprogressors, Fishers 
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Figure 4 (A) Correlation of pretreatment serum CXCL13, sICAM1, MMP3 and IL-8 with clinical disease metrics and ultrasonography scores. Values 
represent Spearman correlation coefficients between serum biomarkers and clinical variables. Stars represent the significance of the correlation 
coefficient: *p<0.05, **p<0.01, ***p<0.001. P values were corrected for multiple testing using Benjamini-Hochberg method. (B) Correlation 
of pretreatment serum CXCL13, sICAM1, MMP3 and IL-8 with synovial histology scores. Values represent Spearman correlation with individual 
eigengene scores adjusted for biopsy joint size, or histology semiquantitative scores. (C) Concentration of serum CXCL13 versus synovial pathotype 
status. (D) Concentration of serum MMP3 versus synovial pathotype status. P values were calculated using student t-test, with correction for multiple 
testing. ACPA, anti-citrullinated protein antibodies; BJ, biopsied joint; CRP, C-reactive protein; CXCL13, C-X-C motif-chemokine-13; DAS28, disease 
activity score-28; DI, Disability Index; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IHC, immunohistochemistry; IL-8, 
interleukin-8; MMP-3, matrix metalloproteinase-3; PD, power Doppler; RF, rheumatoid factor; sICAM1, soluble intercellular adhesion molecule 1; ST, 
synovial thickening; US, ultrasound; VAS, visual analogue scale.
exact test, p=0.029). Thus, despite more intensive treatment 
regimens (including higher rates of biologic use), patients with 
a lympho-myeloid pathotype were significantly more likely to 
develop joint damage progression.
Next, we compared pretreatment/baseline gene expression with 
SHSS progression scores (figure 6B); 46 genes with p value <0.05 
were identified and these included B-cell-associated genes such as 
CD19, FCRL5 and BCMA. In agreement with these findings, we 
further noted that the pretreatment lymphoid eigengene score was 
significantly elevated in patients who had 12-month SHSS scores 
increase versus those who did not (figure 6C), whereas in contrast 
the myeloid and pauci-immune-fibroid eigengene scores were not 
significantly different between progressors versus non-progressors 
(figure 6D,E).
In order to explore mechanistically the link between the 
lympho-myeloid pathotype-associated gene signatures and 
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Figure 5 (A) Clinical changes in disease activity and treatment regimens stratified according to pathotype. (B) Volcano plot showing changes in 
gene expression between baseline and 6 months in patients with a EULAR response. Individual points are coloured by the pathotype in which the 
gene was originally identified, with RA biology-associated genes coloured black. (C) Volcano plot showing changes in gene expression between 
baseline and 6 months in patients with EULAR nonresponse. Genes are coloured as above. (D) Correlation of pretreatment lymphoid, myeloid and 
fibroid eigengene scores with change in DAS28-ESR after 6 months of DMARD treatment. Spearman’s correlation coefficient is shown, along with 
the significance of this value. (E–G) Paired plots for baseline and 6 month lymphoid (E), myeloid (F) and fibroid (G) eigengene scores in patients who 
achieved good or poor clinical responses to DMARD treatment at 6 months by the EULAR response criteria. Patients who achieved a good response, 
or failed to achieve a moderate response, according to EULAR criteria are shown. For each patient, the pretreatment eigengene scores are connected 
to the post-treatment eigengene score, for each of the three eigengenes. Stars represent significance of the difference between pretreatment and 
post-treatment samples using a linear mixed effects model with sample date as a fixed effect and patient as a random effect: *p<0.05, **p<0.01, 
***p<0.001. DAS28, disease activity score-28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EULAR, European 
League Against Rheumatism; MTX, methotrexate.
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Figure 6 (A) 12-month radiographic outcome of patients stratified according to pauci-immune-fibroid/diffuse-myeloid versus lympho-myeloid 
pathotypes. (B) Volcano plot of pretreatment genes differentially expressed between patients who progress radiographically after 1 year (ΔSHSS≥1); 
P values were from the two-sample t-test comparing the progressors and nonprogressors without adjustment. In all, 46 genes with p value <0.05 are 
highlighted in red. (C–E) Baseline eigengene values versus radiographic progression. Lymphoid (C), myeloid (D) and pauci-immune-fibroid (E) baseline 
scores are plotted against progression status (ΔSHSS≥1) at 1 year. **p<0.01 by t-test. (F–G) Identification of clinical and gene expression features 
predictive of radiographic progression at 1 year. Logistic regression, coupled with backward stepwise model selection, was applied to baseline 
clinical parameters against a dependent variable of radiographic progression or not at 12 months to select which clinical covariate contributed the 
most to the prediction; 16 baseline clinical covariates were considered as candidates in the regression model. Baseline variables included gender, 
age, disease duration, ESR, CRP, RF titre, ACPA titre (as continuous variables), VAS, tender and swollen joint number, baseline DAS28-ESR, EULAR 
response at 6 months (categorical), baseline HAQ, 12 max US ST and US PD scores and baseline pathotype (two categories: lympho-myeloid versus 
pauci-immune-fibroid/diffuse-myeloid). Stepwise variable selection yielded a model with eight clinical variables: baseline RF titre, disease duration, 
VAS, swollen joint number, DAS28-ESR, baseline pathotype, 12 max US ST and US PD scores. Selected covariates (46 genes plus 8 clinical covariates) 
were entered simultaneously into a logistic model with an L1 regularisation penalty (LASSO) in order to determine the optimal sparse prediction 
model. We have a better predictive performance of the model where clinical variables were penalised (F, blue-dashed line) than when they were 
not penalised (F, red-dotted line). (G) Nonzero weights associated with the final variables selected by the LASSO regression. ACPA, anti-citrullinated 
peptide antibodies; CRP, C-reactive protein; CXCL13, C-X-C motif-chemokine-13; DAS28-ESR, disease activity score-28-erythrocyte sedimentation rate; 
EULAR, European League Against Rheumatism; HAQ, Health Assessment Questionnaire; JSN, joint space narrowing; LASSO, least absolute shrinkage 
and selection operator; MMP-10, matrix metalloproteinase-10; RF, rheumatoid factor; SHSS, van der Heijde modified Sharp score; SJ, swollen joints; US 
ST, ultrasound synovial thickening; US PD, ultrasound power Doppler; VAS, visual analogue scale.
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structural damage, we investigated the expression of a predefined 
osteoclast gene set derived from Harmonizome database (http:// 
amp. pharm. mssm. edu/ Harmonizome/).
As expected, the osteoclast eigengene score strongly correlated 
with histology scores for both B cells, T cells, plasma cells and 
macrophages (online supplementary figure 5). However, when 
patients were grouped according to pathotype, the demonstration 
that osteoclast eigengene scores were most significantly elevated in 
the lympho-myeloid pathotype patients (p<0.01 lympho-myeloid 
vs diffuse-myeloid and p<0.001 vs pauci-immune) strongly suggests 
that the lymphoid/B-cell component of the immune cell infiltrate 
is orchestrating osteoclast activation and therefore driving joint 
erosion.
Finally, to determine whether baseline clinical and gene expres-
sion data could be combined into a model for predicting radio-
graphic progression, we used two complementary approaches: (i) a 
logistic regression coupled with backward model selection to iden-
tify a minimal set of clinical predictors and (ii) a penalised method 
based on logistic regression with an L1 regularisation penalty 
(LASSO) to identify genes that improve the clinical model.
First, we used backward model selection on baseline clinical 
parameters to identify predictors of radiographic progression. The 
final clinical covariates included baseline RF titre, disease duration, 
VAS, swollen joint number, DAS28-ESR, baseline pathotype, 12 
max US ST and US PD scores. The predictive performance of the 
model evaluated by the optimism-corrected AUC was 0.75 (online 
supplementary figure 6A).
Next, a logistic regression with an L1 regularisation penalty 
(LASSO) was applied on the eight clinical covariates and 46 genes 
(figure 6B) identified as being significantly differentially expressed 
between progressors and nonprogressors. We found that a model 
incorporating RF titre, and the expression of seven genes (SDC1, 
CSF2, DENND1C, CD180, UBASH3A, CXCL1, MMP10, figure 6F), 
yielded the optimal predictor of progression (lambda=0.0631, 
online supplementary figure 6B). After adjustment for optimism, 
our final prediction model was able to discriminate patients with and 
without radiographic progression with an optimism-corrected AUC 
of 0.88 (figure 6G). The predictive performance of the model was 
corrected for potential overfitting by computing the optimism-cor-
rected AUC using a bootstrap method.17 18 These results suggest that 
including both clinical covariates and genes in the model resulted in 
a superior predictive value compared with clinical covariates alone, 
with improved discrimination between patients with and without 
radiographic progression.
dIsCussIOn
It is recognised that RA pathology is highly heterogeneous1–3 19 20; 
however, how such heterogeneity relates to disease activity, prog-
nosis and therapeutic response/outcome has been unclear. In 
addition, the reproducibility of defined histopathological cate-
gories, as well as their stability over time and/or relationship to 
different disease stages also remains uncertain. The work described 
here tackles these problems investigating longitudinally a large, 
treatment-naïve, early RA cohort, with serial synovial sampling 
pre-DMARD and post-DMARD therapy and stringent clinical and 
imaging assessments.
To address the issue of whether synovial heterogeneity is present 
in early versus established RA, we designed gene panels linked 
to lymphoid, macrophage-myeloid and fibroblast cell-lineages, 
trained on synovial subsets we reported in late-stage RA joint 
replacement synovial tissue,2 and tested them in the PEAC cohort. 
The data revealed that prevalent lympho-myeloid, diffuse-myeloid 
and pauci-immune pathotypes are indeed present in early RA tissue 
prior to potentially modifiable therapeutic-sensitive events.
Lympho-myeloid patients had the highest levels of disease activity 
and RF and ACPA seropositivity. Although previous definitions of 
synovial pathotype have referred to lymphoid, myeloid and fibroid 
subgroups importantly, the data analysed herein demonstrate that 
lymphoid-rich patients also showed high expression of myeloid 
genes hence the definition of ‘lympho-myeloid pathotype’ while 
another group of patients had a high expression of myeloid genes 
but low expression of B-cell genes. This latter group also showed a 
diffuse inflammatory infiltrate lacking cellular aggregates and such 
was defined as ‘diffuse myeloid’ while the ‘pauci-immune’ group 
showed a prevalence of stromal cells but almost complete absence 
of immune cells.
Of note, the myeloid gene score was most strongly posi-
tively correlated at baseline with clinical signs and symptoms 
including acute phase reactant, joint counts, DAS28-ESR, 
VAS, HAQ-DI. Importantly, subsequent treatment of these 
patients with DMARDs indicated that the pretreatment levels 
of myeloid genes were most strongly correlated with treatment 
outcome at 6 months and, further, that significant reduction 
of myeloid gene scores was only observed in patients who 
achieved a robust clinical response. This suggests that while 
higher myeloid and lymphoid gene expression is associated 
with increased disease activity, these are the patients more 
likely to respond to broad DMARD immune suppression, 
as pretreatment levels correlated with therapeutic outcome. 
These findings are consistent with previous reports indicating 
that the mean change in sublining macrophages is a strong 
biomarker of treatment response in RA.21 They also indicate 
that the myeloid lineage is a key driver in RA pathogenesis 
and specific therapeutic targeting improves signs and symp-
toms, although not specifically joint damage progression as 
previously suggested in a small cohort of RA patients with 
long-standing disease.22 It is worth reinforcing that the broad 
anti-inflammatory activities of methotrexate via mechanisms 
including activation of the adenosine pathway and down-mod-
ulation of adhesion molecules and proteases23 are supported 
by our data indicating that multiple immune pathways are 
suppressed by methotrexate treatment.
Importantly, patients with high expression of fibroid genes but 
low expression of lymphoid and myeloid genes were found in 27% 
of the cohort, suggesting that this fibroid/pauci-immune pheno-
type previously reported in joint replacement tissue appears to 
be a defined disease endotype and not an end-stage (burned out) 
disease characteristic. Furthermore, the demonstration of a signif-
icant difference in pathotype frequency between joints highlights 
the importance of techniques such as US-guided synovial biopsy 
to enable unbiased recruitment of patients, through capacity to 
sample a wide variety of joints, and thus ensure representative 
sampling. While in our study we did not perform simultaneous 
biopsies of different joints in the same patient, so cannot address 
per se whether synovial pathotype/molecular signatures are stable 
between joints of the same patient, it important to note that 
previous studies have documented stable cellular infiltrates24 and 
specific T-cell oligoclonal expansions25 between joints within the 
same individuals, supporting the notion of a uniform pathology at 
individual patient level across multiple joints.
Regarding the relationship of lineage-specific modules and clin-
ical/therapeutic outcomes, it is noteworthy that while fibroid gene 
scores correlated with less severe disease, these patients still had 
active disease (mean DAS28: 4.9). Moreover, these patients showed 
the poorest subsequent response to DMARD treatment while 
successful drug treatment of the patients with lympho-myeloid and 
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diffuse-myeloid pathotypes resulted in elevation of repair-response 
genes. These results indicate that DMARD treatment primarily 
reduces inflammatory cell infiltrate, thus changing the cellular 
composition of the synovium. Furthermore, as the fibroid genes 
themselves are not reduced with current immune modulatory ther-
apies, our data support the notion that new therapies are required 
to target this specific cell-lineage known to play a critical role 
in pathogenesis/joint damage through epigenetic modifications 
leading to an aggressive phenotype even in the absence of immune/
inflammatory cells.26
The strong correlation between radiographic damage (base-
line and 12 months), lympho-myeloid pathotype and associated 
osteoclast-targeting genes, suggests that active immunological 
processes drive inflammation and structural damage, accelerated 
by high B-cell infiltration levels. This is concordant with previous 
reports showing that B cells and plasma cells produce RANKL 
and TWEAK27–29 while their number was elevated in patients 
with MRI-determined bone oedema and increased RANKL 
expression.30 In contrast, nonprogressors had elevated baseline 
levels of osteoprotegerin (a decoy receptor/negative regulator 
for RANKL-mediated osteoclastogenesis) and fibroid-associ-
ated genes including fibroblast growth factor family members, 
Noggin and cartilage intermediate layer protein (CILP).
In summary, the results presented herein indicate that diverse 
synovial pathotypes are present at an early disease stage prior to 
potential drug-sensitive modification of disease pathology. Further-
more, we demonstrated that specific synovial pathotypes and 
related molecular signatures are associated with clinical pheno-
types, disease outcome/prognosis, that is, radiographic progression 
and moreover that specific molecular signatures predict response 
to therapy. These data support the evaluation of such biomarkers 
within randomised clinical trials with the aim of enriching response 
to current biological therapies by targeting the specific cognate 
pathways expressed in some patients but not others, while offering 
the opportunity, similar to cancer medicine, of developing path-
way-driven/stratified approaches to patients with RA.
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